ESR1 and breast carcinoma: Here we compare the impact of OGT inhibition on a panel of breast cancer cells with a different hormone receptor status: ER- and PR-positive MCF7 and T47D; and receptor-negative MDA-MB-231, BT-549, MDA-MB-468, HCC38 and HCC70.